Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 176

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Lipid-Mediated Enhancement of Transfection by a Nonviral Integrin-Targeting Vector

Hart, Stephen L., Arancibia-Cárcamo, Carolina V., Wolfert, Margreet A., Mailhos, Carolina, O'reilly, Nicola J., Ali, Robin R., Coutelle, Charles, George, Andrew J. T., Harbottle, Richard P., Knight, Andrew M., Larkin, D. Frank P., Levinsky, Roland J., Seymour, Leonard W., Thrasher, Adrian J., Kinnon, Christine · 1998 · Human Gene Therapy

Abstract

Nonviral vectors consisting of integrin-targeting peptide/DNA (ID) complexes have the potential for widespread application in gene therapy. The transfection efficiency of this vector, however, has been limited by endosomal degradation. We now report that lipofectin (L) incorporated into the ID complexes enhances integrin-mediated transfection, increasing Iuciferase expression by more than 100-fold. The transfection efficiency of Lipofectin/Integrin-binding peptide/DNA (LID) complexes, assessed by β-galactosidase reporter gene expression and X-gal staining, was improved from 1% to 10% to over 50% for three different cell lines, and from 0% to approximately 25% in corneal endothelium in vitro. Transfection complexes have been optimized with respect to their transfection efficiency and we have investigated their structure, function, and mode of transfection. Both ID and LID complexes formed particles, unlike the fibrous network formed by lipofectin/DNA complexes (LD). Integrin-mediated transfection by LID complexes was demonstrated by the substantially lower transfection efficiency of LKD complexes in which the integrin-biding peptide was substituted for K16 (K). Furthermore, the transfection efficiency of complexes was shown to be dependent on the amount of integrin-targeting ligand in the complex. Finally, a 34% reduction in integrin-mediated transfection efficiency by LID complexes was achieved with a competing monoclonal antibody. The role of lipofectin in LID complexes appears, therefore, to be that of a co-factor, enhancing the efficiency of integrin-mediated transfection. The mechanism of enhancement is likely to involve a reduction in the extent of endosomal degradation of DNA. Nonviral vectors, consisting of a targeting ligand and a DNA-binding moiety, have great potential for gene therapy due to their safety, simplicity, and capacity for packaging very large DNA molecules. The major limiting factor in the development and application of these vectors, however, has been poor transfection efficiency due, primarily, to endosomal degradation. We have developed an integrin-targeted vector, consisting of a peptide containing a 16-lysine DNA-binding domain and one of a number of possible integrin-binding domains, of approximately 10 amino acid residues. Complexes of peptide and plasmid DNA transfect a number of different cells. The efficiency of this vector has now been enhanced substantially by incorporating small amounts of lipofectin into the complexes. Transfection is largely integrin mediated and the enhancement effect may be explained by lipofectin destabilizing endosomal membranes. Lipofectin-mediated enhancement may be a general approach to improving the efficiency of receptor-mediated vectors.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1089/hum.1998.9.4-575

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 176

Metadata

Authors
Hart, S. L., Arancibia-Cárcamo, C. V., Wolfert, M. A., Mailhos, C., O'reilly, N. J., Ali, R. R., Coutelle, C., George, A. J. T., Harbottle, R. P., Knight, A. M., Larkin, D. F. P., Levinsky, R. J., Seymour, L. W., Thrasher, A. J., & Kinnon, C.
Venue
Human Gene Therapy
Published
1998-03
Volume
9
Issue
4
Pages
575-585
ISSN
  • 1043-0342 (ISSN-L)
  • 1557-7422
OpenAlex
W2023848643
Cited by
176
References
2
FWCI
5.18
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.